Similar articles

• Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood. 2006;107(1):232-240.

  [No authors listed] [No authors listed] Blood. 2019 Jul 4;134(1):95. doi: 10.1182/blood-2019-05-901215. Epub 2019 May 24. Blood. 2019. PMID: 31126918 Free PMC article. No abstract available.
• Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.

  Gao M, Chen G, Wang H, Xie B, Hu L, Kong Y, Yang G, Tao Y, Han Y, Wu X, Zhang Y, Dai B, Shi J. Gao M, et al. Oncotarget. 2016 May 17;7(20):29102-15. doi: 10.18632/oncotarget.8667. Oncotarget. 2016. PMID: 27074555 Free PMC article.
• Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

  Gao M, Gao L, Tao Y, Hou J, Yang G, Wu X, Xu H, Tompkins VS, Han Y, Wu H, Zhan F, Shi J. Gao M, et al. Acta Biochim Biophys Sin (Shanghai). 2014 Jun;46(6):484-91. doi: 10.1093/abbs/gmu030. Epub 2014 May 6. Acta Biochim Biophys Sin (Shanghai). 2014. PMID: 24801128
• Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.

  Steele JM. Steele JM. J Oncol Pharm Pract. 2013 Dec;19(4):348-54. doi: 10.1177/1078155212470388. Epub 2013 Jan 4. J Oncol Pharm Pract. 2013. PMID: 23292972 Review.
• Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

  Kuhn DJ, Orlowski RZ, Bjorklund CC. Kuhn DJ, et al. Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. doi: 10.2174/156800911794519725. Curr Cancer Drug Targets. 2011. PMID: 21247387 Review.